RARE ULTRAGENYX PHARMACEUTICAL INC US FDA Inspections 8-K Filing 2024 - FDA Meeting for Phase 3 Study of GTX-102 for Angelman Syndrome Ultragenyx Pharmaceutical Inc. announced the successful completion of an end-of-Phase 2 meeting with the FDA, supporting its Phase 3 study plans for GTX-102 for Angelman syndrome, including the design, endpoints, and secondary endpoints of the study.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC